Tolerogenic Dendritic Cells Induce Apoptosis-Independent T Cell Hyporesponsiveness of SARS-CoV-2-Specific T Cells in an Antigen-Specific Manner
Open Access
- 2 December 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (23) , 15201
Abstract
Although the global pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still ongoing, there are currently no specific and highly efficient drugs for COVID-19 available, particularly in severe cases. Recent findings demonstrate that severe COVID-19 disease that requires hospitalization is associated with the hyperactivation of CD4+ and CD8+ T cell subsets. In this study, we aimed to counteract this high inflammatory state by inducing T-cell hyporesponsiveness in a SARS-CoV-2-specific manner using tolerogenic dendritic cells (tolDC). In vitro-activated SARS-CoV-2-specific T cells were isolated and stimulated with SARS-CoV-2 peptide-loaded monocyte-derived tolDC or with SARS-CoV-2 peptide-loaded conventional (conv) DC. We demonstrate a significant decrease in the number of interferon (IFN)-γ spot-forming cells when SARS-CoV-2-specific T cells were stimulated with tolDC as compared to stimulation with convDC. Importantly, this IFN-γ downmodulation in SARS-CoV-2-specific T cells was antigen-specific, since T cells retain their capacity to respond to an unrelated antigen and are not mediated by T cell deletion. Altogether, we have demonstrated that SARS-CoV-2 peptide-pulsed tolDC induces SARS-CoV-2-specific T cell hyporesponsiveness in an antigen-specific manner as compared to stimulation with SARS-CoV-2-specific convDC. These observations underline the clinical potential of tolDC to correct the immunological imbalance in the critically ill.Keywords
Funding Information
- Fonds Wetenschappelijk Onderzoek (G049320N, 1S37319N, 1861219N)
- Charcot Foundation (G049320N, 1S37319N, 1861219N)
- Fonds Wetenschappelijk Onderzoek (G049320N, 1S37319N, 1861219N)
- Fonds Wetenschappelijk Onderzoek (G049320N, 1S37319N, 1861219N)
- UZA foundation (G049320N, 1S37319N, 1861219N)
This publication has 61 references indexed in Scilit:
- Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantationTransplantation Research, 2012
- IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction — A comparative study of human clinical-applicable DCClinical Immunology, 2012
- Phase I (Safety) Study of Autologous Tolerogenic Dendritic Cells in Type 1 Diabetic PatientsDiabetes Care, 2011
- Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritisAnnals of the Rheumatic Diseases, 2010
- Tolerogenic Dendritic Cells Generated with Different Immunosuppressive Cytokines Induce Antigen-Specific Anergy and Regulatory Properties in Memory CD4+ T CellsThe Journal of Immunology, 2010
- Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cellsClinical Immunology, 2009
- Executioner caspase-3 and caspase-7 are functionally distinct proteasesProceedings of the National Academy of Sciences, 2008
- Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cellsJournal of Leukocyte Biology, 2007
- DC-based cancer vaccinesJournal of Clinical Investigation, 2007
- Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytesGene Therapy, 2003